$4.29
3.37% yesterday
Nasdaq, Jul 24, 10:28 pm CET
ISIN
US5393192027
Symbol
LIXT

Lixte Biotechnology Holdings Inc Stock News

Neutral
GlobeNewsWire
9 days ago
PASADENA, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced it has received a letter from the Nasdaq Hearings Panel stating that the Company has regained compliance with Nasdaq's Listing Rule 5550(b)(1), the “Equity Rule,” requiring a minimum equity requiremen...
Neutral
GlobeNewsWire
16 days ago
New York, NY, July 09, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a premier investment banking firm, is pleased to announce the closing of a $1.5 million registered direct offering for Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT), in which it served as the exclusive placement agent.
Neutral
GlobeNewsWire
16 days ago
Article Indicates that Inhibition of PP2A Enhances Immunotherapy Response with LIXTE's Proprietary Compound LB100
Neutral
GlobeNewsWire
17 days ago
New York, NY, July 08, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a premier investment banking firm, is pleased to announce the closing of a $5.0 million private placement for Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT), in which it served as the exclusive placement agent.
Neutral
GlobeNewsWire
23 days ago
PASADENA, CALIF, July 02, 2025 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the “Company”), a clinical stage pharmaceutical company, today announced the closing of a private placement with accredited investors for the purchase and sale of approximately $5.0 million of shares of Common Stock (or Pre-Funded Warrants), Series B Convertible Preferred Stock and Common Warra...
Neutral
GlobeNewsWire
24 days ago
PASADENA, CALIF, July 01, 2025 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the “Company”), a clinical stage pharmaceutical company, today announced that, on June 30, 2025 intraday, it entered into a definitive agreement with accredited investors on the purchase and sale of approximately $5.0 million of shares of Common Stock (or Pre-Funded Warrants), Series B Converti...
Neutral
GlobeNewsWire
4 months ago
Pre-Clinical Study in Collaboration with Netherlands Cancer Institute is in addition to LIXTE's Ongoing Clinical Trials for Ovarian and Colorectal Cancers
Neutral
GlobeNewsWire
4 months ago
-Started Two New Clinical Trials,  Collaborating with MD Anderson and The Netherlands Cancer Institute for Treatment of Ovarian and Colorectal Cancer-

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today